LAUNCHING SOON....SITE UNDER PREPARATION....LAUNCHING SOON........SITE UNDER PREPARATION
SUPPORTED BY :
About Us
ExpRNA is a pre-seed startup focused on developing products derived from UK research, empowering healthcare innovation with global impact. The finished product has significant potential to boost global export revenues.
About the project: The RNA therapeutics is an emerging research and business sector, with over 120 FDA-approved human clinical trials currently ongoing (Q12025). Its significance is underscored by the consecutive Nobel Prizes in Medicine awarded for related breakthroughs—microRNA in 2024 and mRNA vaccines in 2023. However, a fundamental challenge in this field is RNA's instability, which continues to hinder growth. With the help AI design methods our project provides a solution to this problem with our RNA formulations (product with IP protection) that are programmable and stable at 95 ℃ thus reducing cost of cold storage supply chain.
Advantages of Our Solutions
Efficiency-driven Technology for Healthcare
Our innovative RNA therapeutics leverage cutting-edge mRNA vaccine technology to drive efficiency in healthcare. Designed for emerging markets, our breakthrough solutions ensure high efficacy by eliminating empty particles, maximizing therapeutic impact with a competitive manufacturing cost (1/5 of existing options in the market). Our efficiency-driven technology can accelerates clinical advancements, enabling faster, more precise treatments.
40-95 °C
RNA formulations are thermal stable.
2-5x efficient
The absence of empty particle increases RNA transfection efficiency.
1/5th in production cost
The absence of empty particle issues and any need for cold supply chain logistics significantly reduces production costs.
Key Features
Innovative Technology for Healthcare
Our delivery platform mimics viral programmability, sensing its environment to selectively deliver RNA therapeutics to target cells. With a shelf life of six months or more without cold storage, it eliminates empty particles by activating only in the presence of RNA molecules, ensuring high efficiency.
PROGRAMMABLE NANO-ROBOTS
Our delivery platform exhibits programmability similar to that of viruses. Like an RNA virus that enters a cell and releases its RNA, these designer biomolecules can 'sense' their surroundings before selectively delivering RNA-based therapeutics to specific cell types.
LONG-TERM SHELF LIFE
Our RNA molecules have a long shelf life of six months or more without the need for cold storage.
FIXING EMPTY PARTICLE PROBLEM
The solution features programmable attributes, meaning it is only activated in the presence of RNA molecules—eliminating the empty particle issue commonly associated with lipid nanoparticles.
NO REFRIGERATION REQUIRED
Store our custom RNA molecules conveniently at room temperature—no refrigeration needed in labs or clinics—and reduce carbon emissions (CO₂).
Our mission is to make RNA medicine accessible worldwide, including in hot and tropical regions with limited electricity and resources.
Our Products (MSP)
AI-enabled designed methods
TBC
Cell specific delivery strategy
TBC
Contract research for sncRNAs application and characterisation
TBC
Optimization of mRNA based protein expression
TBC
Market route:
From molecule to medicine >>>>
Meet the Team
FOUNDER
CO-FOUNDER
Shah Kamranur Rahman
Founder
Shah Rahman combines 15 years of wet lab expertise (mRNA, RNA viruses 10 years, biophysics 5 years) to design artificial biomolecular systems. His work harnesses viral-like programmability to advance modular platforms for gene delivery and synthetic biology.
Syed Asfarul Haque
Co-Founder
Currently serving as the Director of the Center for Cryo-Electron Microscopy in the Department of Structural Biology at St. Jude Children’s Research Hospital, Syed brings over 15 years of experience in structural biology and cryo-EM–based drug discovery. The structural determination of our products will support early adoption and help address potential concerns related to efficacy or safety.
Prof Shozeb Haider
Advisor and Consultant
Dr. Shozeb Haider is a Professor of Computational Biophysics at the UCL School of Pharmacy. His work has advanced the fields of structural biophysics and bioinformatics, with a focus on the structural and functional dynamics of biological macromolecules. He specialises in nucleic acid–based therapeutics, aiming to accelerate their discovery and development. By integrating AI with computational and experimental approaches, Professor Haider is helping to unravel disease mechanisms at the molecular level.
Prof Chris Morris
Advisor and Consultant
Professor Chris Morris, an Associate Professor in the School of Pharmacy at UCL, leads a research group pioneering the discovery and delivery of RNA therapeutics for skin and lung diseases.
Complementing his academic work, Professor Morris serves as Associate Dean for Innovation and Enterprise at UCL's Faculty of Life Sciences. In this role, he spearheads the faculty's research commercialization, industry partnerships, and entrepreneurial initiatives, translating scientific discovery into economic and social impact.
RoboRNA would greatly benefit from his profound expertise in both basic and translational science, as well as his strategic insight into navigating the path from innovation to market.
